Loading
A phase 1/2 trial of VRN110755 in non-small-cell lung cancer and small-cell lung cancer, run by Voronoi, Inc, now recruiting.
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07699328 by Voronoi, Inc, with 315 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-01-01. Interventions recorded: VRN110755. Conditions listed: EGFR-Mutant Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/